Literature DB >> 12842845

Emerging anticoagulant drugs.

Shannon M Bates1, Jeffrey I Weitz.   

Abstract

The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12842845     DOI： 10.1161/01.ATV.0000084827.77945.66

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


  4 in total

Review 1.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

2.  Structural and biochemical characterization of the interaction between KPC-2 beta-lactamase and beta-lactamase inhibitor protein.

Authors:  Melinda S Hanes; Kevin M Jude; James M Berger; Robert A Bonomo; Tracy M Handel
Journal:  Biochemistry       Date:  2009-10-06       Impact factor: 3.162

Review 3.  New anticoagulants for the prevention and treatment of venous thromboembolism.

Authors:  Simon J McRae; Jeffrey S Ginsberg
Journal:  Vasc Health Risk Manag       Date:  2005

4.  SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.

Authors:  Kenneth C Childers; Shaun C Peters; Pete Lollar; Harold Trent Spencer; Christopher B Doering; Paul C Spiegel
Journal:  Blood Adv       Date:  2022-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.